201 related articles for article (PubMed ID: 19160723)
1. Prescription of statins: cost implications of evidence-based treatment applied to a health authority population.
Bradshaw N; Walker R
J Clin Pharm Ther; 1997; 22(5-6):379-89. PubMed ID: 19160723
[TBL] [Abstract][Full Text] [Related]
2. Improving the cost-effectiveness of cardiovascular disease prevention in Australia: a modelling study.
Cobiac LJ; Magnus A; Barendregt JJ; Carter R; Vos T
BMC Public Health; 2012 Jun; 12():398. PubMed ID: 22657090
[TBL] [Abstract][Full Text] [Related]
3. [Secondary prevention after cardiac infarct; therapeutic efficiency--cost-benefit ratio].
Kreuzer J; Kübler W
Internist (Berl); 2001 May; 42(5):713-9. PubMed ID: 11400578
[No Abstract] [Full Text] [Related]
4. Rationale and design of the Post-MI FREEE trial: a randomized evaluation of first-dollar drug coverage for post-myocardial infarction secondary preventive therapies.
Choudhry NK; Brennan T; Toscano M; Spettell C; Glynn RJ; Rubino M; Schneeweiss S; Brookhart AM; Fernandes J; Mathew S; Christiansen B; Antman EM; Avorn J; Shrank WH
Am Heart J; 2008 Jul; 156(1):31-6. PubMed ID: 18585494
[TBL] [Abstract][Full Text] [Related]
5. Implementing guidelines in primary care: can population impact measures help?
Heller RF; Edwards R; McElduff P
BMC Public Health; 2003 Jan; 3():7. PubMed ID: 12542840
[TBL] [Abstract][Full Text] [Related]
6. Under-prescribing of cardiovascular therapies for diabetes in primary care.
Bennett KE; Williams D; Feely J
Eur J Clin Pharmacol; 2003 Apr; 58(12):835-41. PubMed ID: 12698311
[TBL] [Abstract][Full Text] [Related]
7. Improving Adherence to Cardiovascular Therapies: An Economic Evaluation of a Randomized Pragmatic Trial.
Smith DH; O'Keeffe-Rosetti M; Owen-Smith AA; Rand C; Tom J; Vupputuri S; Laws R; Waterbury A; Hankerson-Dyson DD; Yonehara C; Williams A; Schneider J; Dickerson JF; Vollmer WM
Value Health; 2016; 19(2):176-84. PubMed ID: 27021751
[TBL] [Abstract][Full Text] [Related]
8. Effect of combinations of drugs on all cause mortality in patients with ischaemic heart disease: nested case-control analysis.
Hippisley-Cox J; Coupland C
BMJ; 2005 May; 330(7499):1059-63. PubMed ID: 15879390
[TBL] [Abstract][Full Text] [Related]
9. Adherence to statins, beta-blockers and angiotensin-converting enzyme inhibitors following a first cardiovascular event: a retrospective cohort study.
Blackburn DF; Dobson RT; Blackburn JL; Wilson TW; Stang MR; Semchuk WM
Can J Cardiol; 2005 May; 21(6):485-8. PubMed ID: 15917876
[TBL] [Abstract][Full Text] [Related]
10. Changes in prevalence of and prescribing for ischaemic heart disease in Ireland 1990-2002.
Bennett K; Johnson H; Dack P; Shelley E; Feely J
Ir J Med Sci; 2005; 174(3):4-8. PubMed ID: 16285330
[TBL] [Abstract][Full Text] [Related]
11. Drug costs associated with non-adherence to cholesterol management guidelines for primary prevention of cardiovascular disease in an elderly population: the Rotterdam study.
Gumbs PD; Verschuren WM; Mantel-Teeuwisse AK; de Wit AG; Hofman A; Trienekens PH; Stricker BH; de Boer A; Klungel OH
Drugs Aging; 2006; 23(9):733-41. PubMed ID: 17020397
[TBL] [Abstract][Full Text] [Related]
12. Availability and affordability of cardiovascular disease medicines and their effect on use in high-income, middle-income, and low-income countries: an analysis of the PURE study data.
Khatib R; McKee M; Shannon H; Chow C; Rangarajan S; Teo K; Wei L; Mony P; Mohan V; Gupta R; Kumar R; Vijayakumar K; Lear SA; Diaz R; Avezum A; Lopez-Jaramillo P; Lanas F; Yusoff K; Ismail N; Kazmi K; Rahman O; Rosengren A; Monsef N; Kelishadi R; Kruger A; Puoane T; Szuba A; Chifamba J; Temizhan A; Dagenais G; Gafni A; Yusuf S;
Lancet; 2016 Jan; 387(10013):61-9. PubMed ID: 26498706
[TBL] [Abstract][Full Text] [Related]
13. Asymptomatic peripheral arterial disease: is pharmacological prevention of cardiovascular risk cost-effective?
Sigvant B; Henriksson M; Lundin F; Wahlberg E
Eur J Cardiovasc Prev Rehabil; 2011 Apr; 18(2):254-61. PubMed ID: 21450673
[TBL] [Abstract][Full Text] [Related]
14. National Trends in Statin Use and Expenditures in the US Adult Population From 2002 to 2013: Insights From the Medical Expenditure Panel Survey.
Salami JA; Warraich H; Valero-Elizondo J; Spatz ES; Desai NR; Rana JS; Virani SS; Blankstein R; Khera A; Blaha MJ; Blumenthal RS; Lloyd-Jones D; Nasir K
JAMA Cardiol; 2017 Jan; 2(1):56-65. PubMed ID: 27842171
[TBL] [Abstract][Full Text] [Related]
15. Potential savings from an evidence-based consumer-oriented public education campaign on prescription drugs.
Donohue JM; Fischer MA; Huskamp HA; Weissman JS
Health Serv Res; 2008 Oct; 43(5 Pt 1):1557-75. PubMed ID: 18479406
[TBL] [Abstract][Full Text] [Related]
16. Pharmacologic Treatment of Patients With Myocardial Ischemia With No Obstructive Coronary Artery Disease.
Turgeon RD; Pearson GJ; Graham MM
Am J Cardiol; 2018 Apr; 121(7):888-895. PubMed ID: 29394999
[TBL] [Abstract][Full Text] [Related]
17. Comparison of mortality rates in statin users versus nonstatin users in a United States veteran population.
Mehta JL; Bursac Z; Hauer-Jensen M; Fort C; Fink LM
Am J Cardiol; 2006 Oct; 98(7):923-8. PubMed ID: 16996875
[TBL] [Abstract][Full Text] [Related]
18. A model to assess the cost effectiveness of statins in achieving the UK National Service Framework target cholesterol levels.
Wilson K; Marriott J; Fuller S; Lacey L; Gillen D
Pharmacoeconomics; 2003; 21 Suppl 1():1-11. PubMed ID: 12648030
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of preventive cardiovascular pharmacotherapy after coronary artery bypass graft surgery.
Barry AR; Koshman SL; Norris CM; Ross DB; Pearson GJ
Pharmacotherapy; 2014 May; 34(5):464-72. PubMed ID: 24877186
[TBL] [Abstract][Full Text] [Related]
20. Evidence for an age and gender bias in the secondary prevention of ischaemic heart disease in primary care.
Williams D; Bennett K; Feely J
Br J Clin Pharmacol; 2003 Jun; 55(6):604-8. PubMed ID: 12814456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
